Phathom Pharmaceuticals Reports Positive Phase 3 Results for VOQUEZNA in Nocturnal GERD Treatment
Key Insights
Phathom Pharmaceuticals published Phase 3 trial results for VOQUEZNA in the American Journal of Gastroenterology, showing significant improvement in heartburn-free nights versus placebo.
The pHalcon-NERD (search)-301 study demonstrated that VOQUEZNA provided rapid relief from nocturnal GERD (search) symptoms with sustained symptom relief over 20 weeks.
Patient-reported outcomes indicated the treatment was generally well tolerated with common mild adverse events in non-erosive reflux disease (search) patients.
Phathom Pharmaceuticals announced on October 25, 2025, the publication of Phase 3 trial results for VOQUEZNA in the American Journal of Gastroenterology, marking a significant milestone for the company's treatment of non-erosive reflux disease (search) (NERD (search)). The pHalcon-NERD-301 study demonstrated meaningful clinical benefits for patients suffering from nocturnal gastroesophageal reflux disease (search) (GERD (search)) symptoms.
Clinical Efficacy and Patient Outcomes
The Phase 3 trial results showed that VOQUEZNA achieved significant improvement in heartburn-free nights compared to placebo. The initial dose of VOQUEZNA provided rapid relief from nocturnal GERD (search) symptoms, addressing a critical unmet need for patients experiencing nighttime reflux symptoms.
Patient-reported outcomes from the study indicated sustained symptom relief over a 20-week treatment period, suggesting durable therapeutic benefits. The treatment demonstrated consistent efficacy in managing non-erosive reflux disease (search) symptoms throughout the extended study duration.
Safety Profile
VOQUEZNA was generally well tolerated across the patient population in the Phase 3 trial. The safety analysis revealed that common adverse events were mild in nature, supporting the drug's favorable risk-benefit profile for treating nocturnal GERD (search) symptoms.
Market Response and Analyst Sentiment
The publication of positive clinical data has generated significant interest in the investment community. Recent social media discussions have highlighted the potential market impact of the pHalcon-NERD (search)-301 study results, with particular focus on VOQUEZNA's efficacy in treating nighttime GERD (search) symptoms.
Wall Street analysts maintain a positive outlook on Phathom Pharmaceuticals, with four firms issuing buy ratings and no sell ratings in recent months. Analyst price targets for the stock range from $5.0 to $28.0, with a median target of $17.0. Notable price targets include $28.0 from Needham (search)'s Joseph Stringer, $20.0 from HC Wainwright (search)'s Matthew Caufield, and $17.0 from Craig-Hallum (search)'s Chase Knickerbocker.
Institutional Activity
Institutional investor activity has been mixed, with 59 investors adding shares and 69 decreasing positions in the most recent quarter. Significant moves include Frazier Life Sciences Management (search) adding 2,357,210 shares and Millennium Management (search) adding 1,727,134 shares, while Jennison Associates (search) removed their entire 7,042,325 share position.
The company is scheduled to release its Q3 2025 earnings report on October 30, with investors anticipating updates on VOQUEZNA's commercial performance and the impact of the positive clinical data on future guidance.